VIRTUOZZO
5.10.2021 13:02:10 CEST | Business Wire | Press release
Virtuozzo , a high-efficiency virtualization and hyperconverged infrastructure software leader, today announced it has acquired the technology and business of Jelastic , a multi-cloud Platform-as-a-Service (PaaS) software company, following a 10-year partnership.
Bringing Jelastic’s platform and application management capabilities in-house completes Virtuozzo’s core technology stack, delivering a fully integrated solution that supports all relevant anything-as-a-service (XaaS) use cases—from shared hosting to VPS to cloud infrastructure, software-defined storage and application management and modernization.
Virtuozzo offers the first fully integrated, easy-to-use and cost-efficient cloud solution designed for Cloud Service Providers, Managed Service Providers, Hosting Service Providers and their small and medium-sized business (SMB) customers. Virtuozzo also helps service providers increase profitability by providing a comprehensive portfolio of services and management tools.
Many PaaS vendors focus on a single-purpose offering. Jelastic, however, offers a robust, multi-purpose solution that, via the acquisition, will position Virtuozzo as a strong player in the PaaS market and further strengthen Virtuozzo’s position overall in the rapidly growing cloud services space.
“Virtuozzo and Jelastic have been strong partners over the past 10 years because of our complementary technologies and products,” said Alex Fine, CEO of Virtuozzo. “Virtuozzo containers have been incorporated into Jelastic’s Platform-as-a-Service for virtualization since that solution’s inception. Together, our engineering teams have co-developed solutions to enable features required by the market throughout our partnership. And now, with Jelastic joining our team, Virtuozzo can offer a complete, enterprise-grade, turnkey cloud enablement platform with fully integrated orchestration and a single point of management.”
Service Providers Want Simplicity, Automation and Choice
Service providers demand simplification and automation in container and cloud management. Jelastic has been providing a proven production-ready platform to cover these needs for years. The acquisition enables tighter integration and seamless enhancements.
In addition, service providers require a wider set of products to offer to end users. “Freedom of choice” is the core mantra that runs throughout the Jelastic ecosystem. Customers can choose various solutions and services, different types of workloads and management through an automated orchestration.
“Our companies are completely aligned and deeply understand the challenges and opportunities in the service provider industry where Platform-as-a-Service enablement is the key in the process of SaaS-ification and digitalization of its customers,” said Jelastic CEO Ruslan Synytsky. “Our joint partners will benefit from this acquisition since together we become a one-stop shop for Anything-as-a-Service, making it easier to get whatever they need for their users. The joint forces will accelerate the innovation and product development cycles. Together we can raise the bar for the industry standards with the help of our unique technologies that solve real problems of the cloud users.”
Platform-as-a-Service Market Shows Strong Growth
In 2022, the PaaS market is estimated to be worth approximately $71 billion U.S. dollars based on Gartner research . Cloud services (such as PaaS) are anticipated to grow by a high margin at around 27%.
The increased adoption of PaaS among service providers is driven by the end-users’ demand for access to easy-to-manage, high performing and scalable solutions.
By acquiring Jelastic, Virtuozzo can help its service provider partners achieve high ROI by both attracting new end-users and retaining existing customers through enabling XaaS use cases, providing more advanced automation and simplifying their own DevOps processes.
Business as Usual
Business continues as usual, with Jelastic now operating as a division of Virtuozzo—underscoring the value in Jelastic’s brand and technologies. Ruslan Synytsky has been appointed to Chief Technology Officer of Virtuozzo.
Integration of Jelastic’s sales and marketing teams will expand Virtuozzo’s worldwide footprint and brand visibility; and integration of Jelastic’s engineering resources will enable Virtuozzo to accelerate its full stack offering and provide a richer experience across multiple cloud providers.
Terms of the transaction were not disclosed.
About Jelastic
Jelastic is a Multi-Cloud DevOps PaaS for ISVs, telcos, service providers and enterprises needing to speed up development, reduce cost of IT infrastructure, improve uptime and security. The platform automates creation, scaling, clustering and security updates of cloud-native and traditional applications. Jelastic has a unique pay-as-you-use pricing model and is available as public, private, hybrid and multi-cloud in more than 100 data centers worldwide. The platform supports Java, PHP, Ruby, Node.js, Python, .NET, Go environments, as well as Docker and Kubernetes clusters.
About Virtuozzo
Virtuozzo (www.virtuozzo.com ) is a leading, global provider of hybrid virtualization, storage, and cloud enablement software solutions. The Company's software-defined, hyperconverged self-service platform and resource management capabilities enable hosting and service providers to provide end-customers with public and private cloud services. Virtuozzo is an industry pioneer who developed the first commercially available container technology 21 years ago. The Company provides software solutions and services to over 750 service providers worldwide. A significant force in the open-source community, Virtuozzo sponsors and/or is a contributor to numerous open-source projects including KVM, Docker, OpenStack, OpenVZ, CRIU, and the Linux kernel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005403/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom